AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17276866 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resin-based composite adhesive
Number of subjects: 30
Study 17276866 — intervention group
Group type: COMPARATOR
Intervention: ACP-containing orthodontic adhesive
Number of subjects: 30
Study 15851868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pull-ups
Number of subjects: 61
Study 15851868 — intervention group
Group type: COMPARATOR
Intervention: Diapers
Number of subjects: 61
Study 11910567 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC plus GEL
Number of subjects: 69
Study 11910567 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC plus HAS
Number of subjects: 69
Study 11910567 — intervention group
Group type: COMPARATOR
Intervention: HAS
Number of subjects: 69
Study 11910567 — intervention group
Group type: COMPARATOR
Intervention: GEL
Number of subjects: 69
Study 11910567 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 69
Study 10325997 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg anthocyanosides
Number of subjects: 16
Study 10325997 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg anthocyanosides
Number of subjects: 16
Study 10325997 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg anthocyanosides
Number of subjects: 16
Study 10325997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7895921 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with black horizontal and vertical line segments arranged as Ls, Ts, or +s on a pink background
Number of subjects: 2
Study 7895921 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed recognition by younger infants (3 months)
Number of subjects: 2
Study 7895921 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and testing conditions for 6-month-old infants
Number of subjects: 2
Study 2707638 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental calcium 1200 mg/day
Number of subjects: 30
Study 2707638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 330307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (30 ml each 1/2 hr until eight doses, total dose of 4.2 g)
Number of subjects: 169
Study 330307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (higher dose of 8.2 g over 3 1/2‐hr treatment period)
Number of subjects: 169
Study 330307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 169
Study 330307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 330307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate and placebo
Number of subjects: 169
Study 7054318 — intervention group
Group type: EXPERIMENTAL
Intervention: CR virus vaccine
Number of subjects: 306
Study 7054318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 31126567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 20
Study 31126567 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint
Number of subjects: 20
Study 30143479 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention
Number of subjects: 2637
Study 30143479 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey modality
Number of subjects: 2637
Study 30143479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment through Facebook
Number of subjects: 2637
Study 30143479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment through survey panel
Number of subjects: 2637
Study 30143479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment through free internet sources
Number of subjects: 2637
Study 30143479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment through traditional media
Number of subjects: 2637
Study 30143479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment through Google ads
Number of subjects: 2637
Study 27029708 — intervention group
Group type: EXPERIMENTAL
Intervention: AE37 + GM-CSF
Number of subjects: 298
Study 27029708 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF alone
Number of subjects: 298
Study 27029708 — intervention group
Group type: EXPERIMENTAL
Intervention: AE37 + GM-CSF (IHC 1+/2+)
Number of subjects: 298
Study 27029708 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF alone (IHC 1+/2+)
Number of subjects: 298
Study 27029708 — intervention group
Group type: EXPERIMENTAL
Intervention: AE37 + GM-CSF (Triple-negative breast cancer)
Number of subjects: 298
Study 27029708 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF alone (Triple-negative breast cancer)
Number of subjects: 298
Study 24423299 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration in nonpregnant women (n = 8, 15, 16)
Number of subjects: 94
Study 24423299 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration in nonpregnant women
Number of subjects: 94
Study 24423299 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration
Number of subjects: 94
Study 22753918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily
Number of subjects: 188
Study 22753918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily in KRAS wild-type tumors
Number of subjects: 188
Study 22753918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily in KRAS wild-type/EGFR wild-type tumors
Number of subjects: 188
Study 22753918 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg once daily
Number of subjects: 188
Study 22753918 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg once daily in KRAS wild-type tumors
Number of subjects: 188
Study 22753918 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg once daily in KRAS wild-type/EGFR wild-type tumors
Number of subjects: 188
Study 20185783 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg tenecteplase
Number of subjects: 112
Study 20185783 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg tenecteplase
Number of subjects: 112
Study 20185783 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg tenecteplase
Number of subjects: 112
Study 20185783 — intervention group
Group type: COMPARATOR
Intervention: 0.9 mg/kg rtPA
Number of subjects: 112
Study 17681470 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU liaison nurse intervention
Number of subjects: 115
Study 17681470 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard transfer protocol
Number of subjects: 115
Study 14599251 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater empathic accuracy when partner's thoughts and feelings were relationship-threatening.
Number of subjects: 0
Study 14599251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower empathic accuracy when partner's thoughts and feelings were nonthreatening.
Number of subjects: 0
Study 14599251 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer ratings of the degree to which partners tried to avoid the discussion issue.
Number of subjects: 0
Study 11064762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) + DEC (6 mg/kg)
Number of subjects: 40
Study 11064762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) + Albendazole (400 mg)
Number of subjects: 40
Study 11064762 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC (6 mg/kg) + Albendazole (400 mg)
Number of subjects: 40
Study 11064762 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC (6 mg/kg) + Ivermectin (200 micrograms/kg)
Number of subjects: 40
Study 9232072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegia with continuous warm blood
Number of subjects: 60
Study 9232072 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegia with intermittent cold blood with warm reperfusion
Number of subjects: 60
Study 9232072 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegia with intermittent cristalloid using SLF11 solution
Number of subjects: 60
Study 8399865 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V (2 g)
Number of subjects: 60
Study 8399865 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (3 g)
Number of subjects: 60
Study 8399865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2439783 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg/d
Number of subjects: 42
Study 2439783 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg/d
Number of subjects: 42
Study 2439783 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/d
Number of subjects: 42
Study 2439783 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/d
Number of subjects: 42
Study 28244003 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory intervention (three sessions with a health psychologist)
Number of subjects: 64
Study 28244003 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 64
Study 25425539 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg once a day for 3 months
Number of subjects: 58
Study 25425539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23527823 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dry powder apomorphine (VR040)
Number of subjects: 48
Study 23527823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22036610 — intervention group
Group type: COMPARATOR
Intervention: Single treatment pass with Q‐switched alexandrite laser (5.5 J/cm(2), 755 nm, 100‐nanosecond pulse duration, 3‐mm spot size)
Number of subjects: 12
Study 22036610 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 treatment passes with Q‐switched alexandrite laser, 20 minutes apart (R20 method)
Number of subjects: 12
Study 19469686 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (intracranial temperature of 34.5 +/- 0.2 degrees C, maintained for 72 h, n = 12)
Number of subjects: 22
Study 19469686 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (intracranial temperature of 38.0 +/- 0.5, n = 10)
Number of subjects: 22
Study 17430659 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (weekly cisplatin 25 mg/m2 for 6 weeks, radiotherapy at 2 Gy/day to a total of 70 Gy, followed by cisplatin 25 mg/m2 and 5‐fluorouracil 1000 mg/m2 for 3 days every 3 weeks for 3 cycles)
Number of subjects: 80
Study 17430659 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy followed by adjuvant chemotherapy
Number of subjects: 80
Study 17430659 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 80
Study 15675213 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable Portex LMA (PLMA)
Number of subjects: 138
Study 15675213 — intervention group
Group type: COMPARATOR
Intervention: Standard reusable LMA
Number of subjects: 138
Study 15675213 — intervention group
Group type: COMPARATOR
Intervention: Reusable LMA
Number of subjects: 138
Study 15675213 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable PLMA
Number of subjects: 138
Study 15675213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 138
Study 11902595 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (Copaxone)
Number of subjects: 251
Study 11902595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 9591916 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 7888536 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (specific dosage and duration not mentioned)
Number of subjects: 0
Study 3540668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium (2000 mg daily)
Number of subjects: 43
Study 3540668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3540668 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta‐estradiol (combined with progesterone during the second year)
Number of subjects: 43
Study 31195326 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000–3000 mg/day
Number of subjects: 343
Study 31195326 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (TPM) 200–400 mg/day
Number of subjects: 343
Study 28447206 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate-lowering therapy (ULT) for 6 months
Number of subjects: 46
Study 25963221 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR in frail patients
Number of subjects: 244
Study 25963221 — intervention group
Group type: COMPARATOR
Intervention: TAVR in nonfrail patients
Number of subjects: 244
Study 24240384 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (LA) treatment
Number of subjects: 0
Study 24240384 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21888656 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment during pregnancy
Number of subjects: 215
Study 21888656 — intervention group
Group type: COMPARATOR
Intervention: Control (no praziquantel treatment)
Number of subjects: 215
Study 18539339 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 20
Study 18539339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17854525 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GnRH antagonist (2 mg/day) + recombinant LH (375 IU/day)
Number of subjects: 60
Study 17854525 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.25 mg/day GnRH antagonist)
Number of subjects: 60
Study 17854525 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GnRH antagonist + recombinant LH
Number of subjects: 60
Study 17854525 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 15502029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of IV fentanyl formulation (approximately 10‐15 microg/kg; maximum, 400 microg)
Number of subjects: 10
Study 11903396 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP 0.025 microg/kg/min
Number of subjects: 8
Study 11903396 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP 0.025 microg/kg/min
Number of subjects: 8
Study 11903396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9840314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoacid-aminoacid-supplemented very low protein diet (diet K, 0.28 g/kg/d)
Number of subjects: 66
Study 9840314 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-supplemented very low protein diet (diet J, 0.28 g/kg/d)
Number of subjects: 66
Study 9840314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (diet L, 0.575 g/kg/d)
Number of subjects: 66
Study 9840314 — intervention group
Group type: COMPARATOR
Intervention: Usual protein diet (diet M, 1.2 g/kg/d)
Number of subjects: 66
Study 8270442 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanidazole (12 grams/meter2)
Number of subjects: 42
Study 2492422 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (n = 24)
Number of subjects: 72
Study 2492422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 24)
Number of subjects: 72
Study 2492422 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate (n = 24)
Number of subjects: 72
Study 30997631 — intervention group
Group type: COMPARATOR
Intervention: PEDEM supplementation at 12 mg
Number of subjects: 8
Study 30997631 — intervention group
Group type: COMPARATOR
Intervention: PEDEM supplementation at 14 mg
Number of subjects: 8
Study 30997631 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDEM supplementation (various doses)
Number of subjects: 8
Study 28064170 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption (VO2peak) measured in a maximal exercise test on cycle ergometer in men
Number of subjects: 68
Study 28064170 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption (VO2peak) measured in a maximal exercise test on cycle ergometer in women
Number of subjects: 68
Study 26573069 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily for 2 years
Number of subjects: 908
Study 26573069 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further therapy)
Number of subjects: 908
Study 26573069 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily for 2 years (high-risk subgroup)
Number of subjects: 908
Study 26573069 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further therapy) (high-risk subgroup)
Number of subjects: 908
Study 26573069 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily for 2 years (centrally reviewed high-risk subgroup)
Number of subjects: 908
Study 26573069 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further therapy) (centrally reviewed high-risk subgroup)
Number of subjects: 908
Study 23075258 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention (monthly for five months plus usual care)
Number of subjects: 201
Study 23075258 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 201
Study 21861998 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation of a person's choice of toys based on her true or false beliefs about which toys were present.
Number of subjects: 0
Study 19369371 — intervention group
Group type: EXPERIMENTAL
Intervention: LE-0.26
Number of subjects: 10
Study 19369371 — intervention group
Group type: EXPERIMENTAL
Intervention: LE-30
Number of subjects: 10
Study 19369371 — intervention group
Group type: EXPERIMENTAL
Intervention: LE-170
Number of subjects: 10
Study 19369371 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 17039509 — intervention group
Group type: EXPERIMENTAL
Intervention: StarClose
Number of subjects: 596
Study 17039509 — intervention group
Group type: COMPARATOR
Intervention: Manual Compression
Number of subjects: 596
Study 15295410 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-segment scores derived from 20-segment scores using algorithm 2
Number of subjects: 16020
Study 15295410 — intervention group
Group type: COMPARATOR
Intervention: 20-segment perfusion scores
Number of subjects: 16020
Study 15295410 — intervention group
Group type: COMPARATOR
Intervention: derived 17-segment scores
Number of subjects: 16020
Study 15295410 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-segment model
Number of subjects: 16020
Study 15295410 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion algorithm 2
Number of subjects: 16020
Study 15295410 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal prognostic cutoff value for either model
Number of subjects: 16020
Study 11369630 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 10 microg/kg per day subcutaneously from day 1 through neutrophil recovery
Number of subjects: 42
Study 9635705 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1147
Study 9635705 — intervention group
Group type: COMPARATOR
Intervention: Control (no preoperative radiotherapy)
Number of subjects: 1147
Study 1927938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide dinitrate 120 mg
Number of subjects: 14
Study 1927938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 120 mg
Number of subjects: 14
Study 1927938 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of isosorbide dinitrate and diltiazem
Number of subjects: 14
Study 1927938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6314720 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (0.6%)
Number of subjects: 306
Study 6314720 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin 910 (0.7%)
Number of subjects: 306
Study 6314720 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 306
Study 6314720 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin 910
Number of subjects: 306
Study 30661513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 50 mg (V50)
Number of subjects: 1395
Study 30661513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg (V100)
Number of subjects: 1395
Study 30661513 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine extended release 4 mg (TER4)
Number of subjects: 1395
Study 30661513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 28329397 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (2-3 g/daily)
Number of subjects: 30
Study 28329397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29809375 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg per oral once daily for three months
Number of subjects: 60
Study 29809375 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg per oral once daily for three months
Number of subjects: 60
Study 29809375 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 23485476 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept 80 mg
Number of subjects: 248
Study 23485476 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept 160 mg
Number of subjects: 248
Study 23485476 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 248
Study 21206331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nafamostat mesilate
Number of subjects: 286
Study 21206331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 20441124 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitro ceramic
Number of subjects: 15
Study 20441124 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 15
Study 17031391 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) (Clarinol)
Number of subjects: 118
Study 17031391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 118
Study 15359356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water HB (bicarbonate-rich), 1 liter per day for 28 days
Number of subjects: 60
Study 15359356 — intervention group
Group type: COMPARATOR
Intervention: Mineral water HS (sulfate-rich), 1 liter per day for 28 days
Number of subjects: 60
Study 11344383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 20 ng/kg/min
Number of subjects: 130